RAP Composition for OPC Differentiation and Remyelination in MS

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies for multiple sclerosis (MS) do not effectively address the need for stimulation of remyelination, leading to progressive disability and death due to the lack of agents capable of mitigating or resolving irreversible damage caused by immune-mediated demyelinating lesions.

Innovation Solution

Administering receptor associated protein (RAP) or its derivatives, variants, or fragments to inhibit low-density lipoprotein receptor-related protein-1 (LRP1) and block pathological activation of RhoA, promoting the differentiation of oligodendrocyte progenitor cells into mature oligodendrocytes, enhancing myelin protein expression, and facilitating remyelination.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current approved therapies for MS are used, then the severity and frequency of MS attacks are reduced, but the ability to stimulate remyelination and address irreversible damage is not improved

Engineering Contradiction:

Improveremyelination capabilityVSAvoiddisease progression control

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent uses oligodendrocyte progenitor cells (OPCs) as intermediary cells that are administered to the patient to mediate the remyelination process. These OPCs serve as a bridge between the damaged myelin and the need for repair, differentiating into mature oligodendrocytes that can form new myelin sheaths around axons, thereby addressing the unmet need for remyelination stimulation while current therapies focus on reducing attack frequency

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If the immune system actively destroys myelin during the inflammatory phase, then MS attacks occur, but irreversible damage and neuronal dysfunction result

Engineering Contradiction:

Improveimmune-mediated destructionVSAvoidneuronal integrity

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The patent administers OPCs before or during the inflammatory phase to establish a reservoir of repair-capable cells that can rapidly differentiate and remyelinate axons. This preliminary action ensures that when immune-mediated destruction occurs, there are already OPCs in place that can quickly respond and restore myelin, preventing irreversible neuronal damage even though the harmful immune attack cannot be completely prevented

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The patent converts the harmful effect of immune-mediated demyelination into a beneficial stimulus by exploiting the fact that myelin debris and inflammatory signals actually promote OPC differentiation and proliferation. The harmful immune attack creates conditions that, when combined with administered OPCs, trigger enhanced remyelination responses, turning the destructive inflammatory environment into a catalyst for repair

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20260014230A1Methods and compositions for promoting OPC differentiation and remyelination using receptor associated protein (RAP)

Publication Date: 2026.01.15 NOVORON BIOSCIENCE INC

AI summary

The present disclosure relates to methods and compositions using RAP, a derivative of RAP, a variant of RAP, or a fragment of RAP to inhibit LRP1, a myelin debris receptor. The methods and compositions involve increasing, promoting, restoring, and/or enhancing differentiation of oligodendrocyte progenitor cells, myelin protein expression, mature oligodendrocyte marker expression, and/or myelination. The methods and compositions disclosed herein inhibit or block pathological activation of RhoA in OPCs. The methods and compositions also involve alleviating one or more symptoms of MS and treating MS, including slowing or stopping MS progression.